☆ 4.7 Article

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

Journal for ImmunoTherapy of Cancer (2015)

Get Full Text
Add to Collection

Journal

Journal for ImmunoTherapy of Cancer
Volume 3, Issue Suppl 2, Pages O8

Publisher

Springer Nature
DOI: 10.1186/2051-1426-3-s2-o8

Keywords

-

Categories

Immunology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.